Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T- and B-cell depleted grafts in children

Haematologica

Volumn 95, Issue 8, 2010, Pages 1381-1388

  Pfeiffer, Matthias M ^a   Feuchtinger, Tobias ^a   Teltschik, Heiko Manuel ^a   Schumm, Michael ^a   Müller, Ingo ^a   Handgretinger, Rupert ^a   Lang, Peter ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Haploidentical transplantation; Multi color flow cytometry; NK cells

Indexed keywords

BUSULFAN; CD16 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; CLOFARABINE; FLUDARABINE; HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATURAL KILLER CELL RECEPTOR; OKT 3; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; APLASTIC ANEMIA; ARTICLE; B CELL DEPLETION; CANCER RELAPSE; CANCER SURVIVAL; CELL SELECTION; CELL STRAIN K 562; CHILD; CONTROLLED STUDY; CYTOLYSIS; EWING SARCOMA; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HAPLOIDENTICAL STEM CELL TRANSPLANTATION; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HOMOZYGOTE; HUMAN; HUMAN CELL; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKEMIA CELL; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; OUTCOME ASSESSMENT; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRESCHOOL CHILD; SCHOOL CHILD; SOLID TUMOR; STEM CELL TRANSPLANTATION; T CELL DEPLETION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ALLELES; ANTIGENS, CD3; ANTIGENS, CD56; B-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA-C ANTIGENS; HUMANS; INFANT; K562 CELLS; KILLER CELLS, NATURAL; RECEPTORS, IGG; RECEPTORS, NATURAL KILLER CELL; RECURRENCE; T-LYMPHOCYTES; YOUNG ADULT;

EID: 77956021364     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.021121     Document Type: Article

References (38)

1. Handgretinger R, Klingebiel T, Lang P, Schumm M, Neu S, Geiselhart A, et al. Megadose transplantation of purifiedperipheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant. 2001;27(8):777-83.
2. Lang P, Handgretinger R, Niethammer D, Schlegel PG, Schumm M, Greil J, et al. Transplantation of highly purified CD34+progenitor cells from unrelated donors in pediatric leukemia. Blood. 2003;101(4):1630-6.
3. Marks DI, Khattry N, Cummins M, Goulden N, Green A, Harvey J, et al. Haploidentical stem cell transplantation for children with acute leukaemia. Br J Haematol. 2006;134(2):196-201.
4. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225-74.
5. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-100.
6. Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL, et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood. 2007;109(11):5058-61.
7. Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol. 2004;172(1):644-50.
8. Silva MR, Hoffman R, Srour EF, Ascensao JL. Generation of human natural killer cells from immature progenitors does not require marrow stromal cells. Blood. 1994;84(3):841-6.
9. Mrozek E, Anderson P, Caligiuri MA. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood. 1996;87(7):2632-40.
10. Carayol G, Robin C, Bourhis JH, Bennaceur-Griscelli A, Chouaib S, Coulombel L, et al. NK cells differentiated from bone marrow, cord blood and peripheral blood stem cells exhibit similar phenotype and functions. Eur J Immunol. 1998;28(6):1991-2002.
11. Mingari MC, Vitale C, Cantoni C, Bellomo R, Ponte M, Schiavetti F, et al. Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor. Eur J Immunol. 1997;27(6):1374-80.
12. Miller JS, McCullar V. Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2. Blood. 2001;98(3):705-13.
13. Freud AG, Yokohama A, Becknell B, Lee MT, Mao HC, Ferketich AK, et al. Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med. 2006;203(4):1033-43.
14. Colucci F, Caligiuri MA, Di Santo JP. What does it take to make a natural killer? Nat Rev Immunol. 2003;3(5):413-25.
15. Freud AG, Caligiuri MA. Human natural killer cell development. Immunol Rev. 2006;214:56-72.
16. Galy A, Travis M, Cen D, Chen B. Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity. 1995;3(4):459-73.
17. Miller JS, Alley KA, McGlave P. Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: identification of a CD34+7+ NK progenitor. Blood. 1994;83(9):2594-601.
18. Pfeiffer M, Stanojevic S, Feuchtinger T, Greil J, Handgretinger R, Barbin K, et al. Rituximab mediates in vitro antileukemic activity in pediatric patients after allogeneic transplantation. Bone Marrow Transplant. 2005;36(2):91-7.
19. Ruggeri L, Aversa F, Martelli MF, Velardi A. Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. Immunol Rev. 2006;214:202-18.
20. Vago L, Forno B, Sormani MP, Crocchiolo R, Zino E, Di Terlizzi, et al. Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. Blood. 2008;112(8):3488-99.
21. Nguyen S, Dhedin N, Vernant JP, Kuentz M, Al Jijakli A, Rouas-Freiss N, et al. NKcell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood. 2005;105(10):4135-42.
22. Huntington ND, Legrand N, Alves NL, Jaron B, Weijer K, Plet A, et al. IL-15 transpresentation promotes human NK cell development and differentiation in vivo. J Exp Med. 2009;206(1):25-34.
23. Ma A, Koka R, Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol. 2006;24:657-79.
24. Pfeiffer M, Schumm M, Feuchtinger T, Dietz K, Handgretinger R, Lang P. Intensity of HLA class I expression and KIR-mismatch determine NK-cell mediated lysis of leukaemic blasts from children with acute lymphatic leukaemia. Br J Haematol. 2007;138(1):97-100.
25. Feuchtinger T, Pfeiffer M, Pfaffle A, Teltschik HM, Wernet D, Schumm M, et al. Cytolytic activity of NK cell clones against acute childhood precursor-B-cell leukaemia is influenced by HLA class I expression on blasts and the differential KIR phenotype of NK clones. Bone Marrow Transplant. 2009;43(11):875-81.
26. Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res. 2008;68(19):8049-57.
27. Otto M, Barfield RC, Martin WJ, Iyengar R, Leung W, Leimig T, et al. Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma. Clin Cancer Res. 2005;11(23):8486-91.
28. Bishara A, De Santis D, Witt CC, Brautbar C, Christiansen FT, Or R, et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens.2004;63(3):204-11.
29. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102(3): 814-9.
30. Lowe EJ, Turner V, Handgretinger R, Horwitz EM, Benaim E, Hale GA, et al. Tcell alloreactivity dominates natural killer cell alloreactivity in minimally T-celldepleted HLA-non-identical paediatric bone marrow transplantation. Br J Haematol. 2003;123(2):323-6.
31. Cooley S, McCullar V, Wangen R, Bergemann TL, Spellman S, Weisdorf DJ, et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood. 2005;106(13):4370-6.
32. Kroger N, Binder T, Zabelina T, Wolschke C, Schieder H, Renges H, et al. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIRligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation. 2006;82(8):1024-30.
33. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005;436(7051):709-13.
34. Leung W, Handgretinger R, Iyengar R, Turner V, Holladay MS, Hale GA. Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma. Br J Cancer. 2007;97(4):539-42.
35. Yu J, Venstrom JM, Liu XR, O'Reilly R,Pring J, Hasan RS, et al. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function following T-cell depleted allogeneic hematopoietic cell transplantation. Blood. 2009;113(16):3875-84.
36. Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, et al. Antileukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood. 2009;113(13):3119-29.
37. Fischer JC, Ottinger H, Ferencik S, Sribar M, Punzel M, Beelen DW, et al. Relevance of C1 and C2 epitopes for hemopoietic stem cell transplantation: role for sequential acquisition of HLA-C-specific inhibitory killer Ig-like receptor. J Immunol. 2007;178(6):3918-23.
38. Giebel S, Locatelli F, Wojnar J, Velardi A, Mina T, Giorgiani G, et al. Homozygosity for human leucocyte antigen-C ligands of KIR2DL1 is associated with increased risk of relapse after human leucocyte antigen-C-matched unrelated donor haematopoietic stem cell transplantation. Br J Haematol. 2005;131(4):483-6.